Nicolet Advisory Services LLC Raises Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Nicolet Advisory Services LLC raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 24.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,059 shares of the medical equipment provider’s stock after buying an additional 209 shares during the quarter. Nicolet Advisory Services LLC’s holdings in Intuitive Surgical were worth $414,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ISRG. M&G Plc acquired a new position in shares of Intuitive Surgical in the first quarter valued at approximately $1,318,000. Wintrust Investments LLC boosted its holdings in shares of Intuitive Surgical by 4.4% during the first quarter. Wintrust Investments LLC now owns 40,292 shares of the medical equipment provider’s stock worth $16,080,000 after purchasing an additional 1,696 shares during the last quarter. Delos Wealth Advisors LLC grew its position in shares of Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 57 shares during the period. Brighton Jones LLC increased its stake in Intuitive Surgical by 5.2% in the first quarter. Brighton Jones LLC now owns 9,314 shares of the medical equipment provider’s stock valued at $3,717,000 after purchasing an additional 457 shares during the last quarter. Finally, Blair William & Co. IL lifted its position in Intuitive Surgical by 13.3% during the first quarter. Blair William & Co. IL now owns 448,575 shares of the medical equipment provider’s stock worth $179,022,000 after buying an additional 52,693 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Transactions at Intuitive Surgical

In related news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Myriam Curet sold 5,318 shares of the company’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total value of $1,971,169.88. Following the transaction, the executive vice president now directly owns 298 shares of the company’s stock, valued at $110,456.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of the stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The disclosure for this sale can be found here. Insiders sold a total of 17,956 shares of company stock valued at $6,927,011 over the last quarter. Company insiders own 0.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ISRG shares. BTIG Research raised their target price on shares of Intuitive Surgical from $451.00 to $459.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Morgan Stanley upped their price target on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. The Goldman Sachs Group started coverage on Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective on the stock. Piper Sandler raised their price target on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a report on Friday. Finally, Jefferies Financial Group increased their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $438.74.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG traded up $38.87 during trading hours on Friday, hitting $455.01. 4,201,310 shares of the company’s stock traded hands, compared to its average volume of 1,643,900. The company’s fifty day simple moving average is $422.05 and its two-hundred day simple moving average is $394.21. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $456.81. The company has a market cap of $161.39 billion, a price-to-earnings ratio of 82.13, a price-to-earnings-growth ratio of 5.87 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.40% and a net margin of 27.65%. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.18 EPS. On average, analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.